All Oncology News

Matthew Borst, MD, highlights the need for neoadjuvant therapy versus upfront surgery in newly diagnosed patients, effective treatment management for recurrent platinum-sensitive disease, and what to do in the third-line setting and beyond.

Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.

Combination therapy with the PD-L1 inhibitor atezolizumab and the MEK inhibitor cobimetinib failed to improve overall survival versus regorafenib in previously treated patients with locally advanced or metastatic colorectal cancer, according to topline findings from the phase III IMblaze370 study.

Heather Dalton, MD, discusses the developing standard of care for the frontline treatment of patients with ovarian cancer.

Xiao X. Wei, MD, MAS, discusses managing possible adverse events of different systemic therapies in kidney and bladder cancer.

Rena D. Callahan, MD, discusses controversies in the management of early-stage HR-positive breast cancer and neoadjuvant trial designs for these patients.

Aashini Master, DO, discusses efforts to integrate nutrition and health into breast cancer survivorship.

Findings from the phase III TAGS trial showed that TAS-102 (trifluridine/tipiracil; Lonsurf) extended overall survival in previously treated patients with metastatic gastric cancer.

Snehal Bhoola, MD, discusses the implementation of enhanced recovery after surgery in ovarian cancer.

Guru P. Sonpavde, MD, navigates through the treatment landscape of urothelial carcinoma.

The European Commission has approved olaparib tablets (Lynparza) as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer.

Quizartinib improved overall survival compared with chemotherapy in patients with FLT3-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation, according to findings from the phase III QuANTUM-R study.

Saad Z. Usmani, MD, discusses the current state of immune checkpoint inhibitors in hematologic cancers, recent setbacks, and ongoing studies that could further shape the landscape.

Michael R. Grunwald, MD, discusses new and emerging agents in acute myeloid leukemia and acute lymphoblastic leukemia, as well as sequencing and toxicity challenges with these treatments.

Peter Voorhees, MD, discusses treatments for patients with early relapsed multiple myeloma and previews future research efforts.

Lyndsay Willmott, MD, discusses the use of PARP inhibitors in patients with ovarian cancer and details the mechanisms of resistance that have been identified so far.

The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Bradley J. Monk, MD, FACOG, FACS, discusses the promise of new therapies and regimens in patients with ovarian cancer in the recurrent setting.

Bradley A. McGregor, MD, discusses the growth of combination therapy in the treatment of patients with kidney cancer.

Maggie DiNome, MD, discusses the evolution of surgical approaches in patients with early-stage breast cancer.

The FDA has granted a priority review to a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.

The National Institute for Health and Care Excellence has authorized the use of midostaurin in combination with standard chemotherapy for the treatment of patients with newly diagnosed FLT3-positive acute myeloid leukemia.

The FDA has approved combination therapy with dabrafenib and trametinib for the treatment of patients with unresectable or metastatic BRAF V600E–positive anaplastic thyroid cancer.

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

Results from a recent study may show why some patients with chronic lymphocytic leukemia are resistant to tisagenlecleucel, while potentially offering a pathway to enhance patient response.

A supplemental biologics license application has been submitted to the FDA for the use of pembrolizumab in combination with standard chemotherapy as a treatment for patients with metastatic squamous non–small cell lung cancer.

The FDA has issued a complete response letter to Sandoz (Novartis) regarding a biologics license application for the rituximab biosimilar GP2013.

Saad Z. Usmani, MD, discusses the clinical applications of minimal residual disease and managing patients with relapsed/refractory multiple myeloma.

Susan A. McCloskey, MD, discusses the use of postoperative radiation in patients with breast cancer.